CPRX
Price
$22.78
Change
+$0.12 (+0.53%)
Updated
Jan 17 closing price
Capitalization
2.72B
53 days until earnings call
ERAS
Price
$1.85
Change
-$0.01 (-0.54%)
Updated
Jan 17 closing price
Capitalization
523.05M
61 days until earnings call
Ad is loading...

CPRX vs ERAS

Header iconCPRX vs ERAS Comparison
Open Charts CPRX vs ERASBanner chart's image
Catalyst Pharmaceuticals
Price$22.78
Change+$0.12 (+0.53%)
Volume$4.93M
Capitalization2.72B
Erasca
Price$1.85
Change-$0.01 (-0.54%)
Volume$1.39M
Capitalization523.05M
CPRX vs ERAS Comparison Chart
Loading...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CPRX vs. ERAS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPRX is a Hold and ERAS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CPRX: $22.78 vs. ERAS: $1.85)
Brand notoriety: CPRX and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CPRX: 430% vs. ERAS: 101%
Market capitalization -- CPRX: $2.72B vs. ERAS: $523.05M
CPRX [@Biotechnology] is valued at $2.72B. ERAS’s [@Biotechnology] market capitalization is $523.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPRX’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • CPRX’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, CPRX is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPRX’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 3 bullish TA indicator(s).

  • CPRX’s TA Score: 5 bullish, 4 bearish.
  • ERAS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CPRX is a better buy in the short-term than ERAS.

Price Growth

CPRX (@Biotechnology) experienced а +3.92% price change this week, while ERAS (@Biotechnology) price change was -21.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CPRX is expected to report earnings on May 07, 2025.

ERAS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CPRX($2.72B) has a higher market cap than ERAS($523M). CPRX YTD gains are higher at: 9.152 vs. ERAS (-26.295). CPRX has higher annual earnings (EBITDA): 211M vs. ERAS (-151.33M). CPRX has more cash in the bank: 442M vs. ERAS (319M). CPRX has less debt than ERAS: CPRX (3.28M) vs ERAS (52.9M). CPRX has higher revenues than ERAS: CPRX (460M) vs ERAS (0).
CPRXERASCPRX / ERAS
Capitalization2.72B523M520%
EBITDA211M-151.33M-139%
Gain YTD9.152-26.295-35%
P/E Ratio19.31N/A-
Revenue460M0-
Total Cash442M319M139%
Total Debt3.28M52.9M6%
FUNDAMENTALS RATINGS
CPRX: Fundamental Ratings
CPRX
OUTLOOK RATING
1..100
76
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
PROFIT vs RISK RATING
1..100
13
SMR RATING
1..100
34
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
80
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CPRXERAS
RSI
ODDS (%)
Bullish Trend 11 days ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 11 days ago
77%
Bearish Trend 11 days ago
85%
Momentum
ODDS (%)
Bullish Trend 11 days ago
87%
Bullish Trend 11 days ago
83%
MACD
ODDS (%)
N/A
Bullish Trend 11 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 11 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
80%
Bearish Trend 11 days ago
90%
Advances
ODDS (%)
Bullish Trend 24 days ago
81%
Bullish Trend 16 days ago
79%
Declines
ODDS (%)
Bearish Trend 12 days ago
68%
Bearish Trend about 1 month ago
86%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
78%
Bearish Trend 11 days ago
90%
Aroon
ODDS (%)
Bearish Trend 11 days ago
56%
Bearish Trend 11 days ago
90%
View a ticker or compare two or three
Ad is loading...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RAEBX42.210.36
+0.86%
American Funds AMCAP R2E
MFLDX23.670.20
+0.85%
Cromwell Long Short Institutional
TILCX23.940.12
+0.50%
T. Rowe Price Lrg Cp Va I
SMDRX19.920.08
+0.40%
Hartford Schroders US MidCap Opps SDR
IVVIX20.440.06
+0.29%
Macquarie Smid Cap Core Fund Class I

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with CMPX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then CMPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
+0.53%
CMPX - CPRX
40%
Loosely correlated
+4.00%
VIR - CPRX
39%
Loosely correlated
+0.60%
ALDX - CPRX
37%
Loosely correlated
+1.26%
ERAS - CPRX
36%
Loosely correlated
-0.54%
KYMR - CPRX
36%
Loosely correlated
+0.79%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-0.54%
XNCR - ERAS
52%
Loosely correlated
-3.94%
KYMR - ERAS
48%
Loosely correlated
+0.79%
INZY - ERAS
46%
Loosely correlated
N/A
PLRX - ERAS
46%
Loosely correlated
-3.36%
BEAM - ERAS
46%
Loosely correlated
+0.17%
More